Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
An article from
Dive Brief
Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
Published July 20, 2026
Tempus AI struck an agreement to buy Personalis, which makes a molecular residual disease test for cancer.
Tempus AI strikes $1.5B deal for Personalis, betting big on AI-powered cancer detection
Tempus buys out cancer genomics partner Personalis in $1.5 billion deal
Tempus AI Scoops Up Genomics Play For $1.5 Billion; But Shares Dive
Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition - Personalis (NASDAQ:PSNL), Tempu
Why Is Tempus AI Stock Volatile Tuesday? - Personalis (NASDAQ:PSNL), Tempus AI (NASDAQ:TEM)
Merck Reportedly Goes To Bat In Takeover Battle
Massive Bio Partners With FOMAT to Expand Cancer Patient Prescreening for Clinical Trial Access
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
TytoCare Names Adam Pellegrini as CEO and Closes $25M+ Growth Round to Scale AI-First Clinical Enablement Platform
